Clinical Trials on Facial Melasma in Australia

Total 580 results

Peter MacCallum Cancer Centre, Australia
Melbourne Health

Completed

NMP in Relapsed / Refractory Myeloma

Multiple Myeloma

Australia
Peter MacCallum Cancer Centre, Australia
Janssen, LP

Recruiting

CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study (CARAMEL)

Extramedullary Myeloma

Australia
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (USA), Inc.

Withdrawn

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma

United States, Germany, France, Australia, Spain, Switzerland, United Kingdom
Ichnos Sciences SA

Not yet recruiting

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Australia
Peter MacCallum Cancer Centre, Australia
The Leukemia and Lymphoma Society

Completed

A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone

Lymphoma | Multiple Myeloma

Australia
Cancer Trials Australia
Human Genome Sciences Inc.

Unknown

A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia

Symptomatic Waldenstroms Macroglobulinaemia

Australia
Gilead Sciences

Terminated

Efficacy Study of CYT997 in Multiple Myeloma

Relapsed and Refractory Multiple Myeloma

Australia
Murdoch Childrens Research Institute
National Health and Medical Research Council, Australia; Royal Children's Hospital and other collaborators

Recruiting

Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents (GenV)

Communicable Diseases | Quality of Life | Inflammation | Obesity | Congenital Abnormalities | Genetics | Healthy Aging | Child Development | Diet | Mental Health | Disability | Injuries | Cognition | Child Health | Environmental Exposure | Noncommunicable Diseases | Physical Fitness | Intergenerational Relations | Social Determinants... and other conditions

Australia
Christoph Aufricht

Recruiting

ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank

Proteinuria | Focal Segmental Glomerulosclerosis | Nephrotic Syndrome | Nephrotic Syndrome Steroid-Resistant

Austria
AbbVie

Withdrawn

A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment

Multiple Myeloma

Australia
Peter MacCallum Cancer Centre, Australia
Janssen-Cilag Ltd.

Completed

Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse

Multiple Myeloma

Australia
Hoffmann-La Roche

Completed

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Malignant Melanoma, Neoplasms

Spain, New Zealand, Hungary, Serbia, Germany, Portugal, Netherlands, Greece, Australia
Eucure (Beijing) Biopharma Co., Ltd

Active, not recruiting

A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers

Melanoma | Pancreatic Ductal Adenocarcinoma

United States, Australia
Merck Sharp & Dohme LLC
Eisai Inc.

Completed

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

Advanced Melanoma

Canada, United States, Australia, Spain, Sweden
IDEAYA Biosciences

Recruiting

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Colorectal Cancer | Metastatic Uveal Melanoma | Cutaneous Melanoma | Other Solid Tumors

United States, Australia, Canada
Novartis Pharmaceuticals

Completed

Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases

Bone Neoplasms

Australia
Peter MacCallum Cancer Centre, Australia
Sanofi; Regeneron Pharmaceuticals; Monash University; University of Adelaide; University...

Recruiting

Deep sequencIng in Cutaneous Squamous CEll caRciNomas (DISCERN)

Neoplasms | Cutaneous Squamous Cell Carcinoma of the Head and Neck | Non-melanoma Skin Cancer | Cutaneous Squamous Cell Carcinoma

Australia
Novartis Pharmaceuticals

Terminated

A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

Uveal Melanoma

United States, Australia, France, Netherlands, Spain, Norway
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Australia
Smith & Nephew, Inc.

Completed

A Study of the Safety and Performance of the MINITAC◊ Titanium 2.0 Suture Anchor (MINITAC)

Hallux Valgus Repairs | Medial or Lateral Instability Repairs/Reconstructions | Achilles Tendon Repairs/Reconstructions | Midfoot Reconstructions | Metatarsal Ligament/Tendon Repairs/Reconstructions | Scapholunate Ligament Reconstructions | Ulnar or Radial Collateral Ligament Reconstructions | Lateral... and other conditions

Australia
Peter MacCallum Cancer Centre, Australia

Completed

Panobinostat Biological Correlates Study (VEG VCA1)

Multiple Myeloma | Nodal Lymphoma | Lymphoma With Cutaneous Involvement | Lymphoma in Leukemic Phase | Marrow Involvement With Lymphoma

Australia
Medical University of Vienna

Unknown

Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma (M3)

Melanoma

Austria
Hoffmann-La Roche

Completed

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

Malignant Melanoma

United States, Australia
GlaxoSmithKline

Completed

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

Cancer

Australia, United States
Cerebral Therapeutics LLC

Terminated

Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization

Refractory Epilepsy

Israel, Australia
Ludwig Institute for Cancer Research
Institute of Cancer Research, United Kingdom

Completed

Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma

Melanoma

United Kingdom, Australia, New Zealand
Merck Sharp & Dohme LLC

Terminated

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

Advanced/Metastatic Melanoma

United States, Australia, Chile, France, Germany, Israel, Italy, Korea, Republic of, Norway, South Africa, Spain
OncoSec Medical Incorporated
Merck Sharp & Dohme LLC

Active, not recruiting

Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment (Keynote-695)

Stage III/IV Melanoma

United States, Australia, Canada, Italy, Switzerland
Neurocrine Biosciences

Terminated

Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

Focal Onset Seizure | Focal Onset Epilepsy

Spain, Australia, Belgium, Czechia, France, Hungary, Italy
GlaxoSmithKline

Terminated

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

Melanoma and Brain Metastases

United States, Australia
Iovance Biotherapeutics, Inc.

Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Melanoma | Metastatic Melanoma | Unresectable Melanoma

United States, Spain, Australia, France, Netherlands, Italy, Canada, Sweden
Peter MacCallum Cancer Centre, Australia
The Leukemia and Lymphoma Society

Completed

ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells

Multiple Myeloma | Cutaneous Lymphoma

Australia
Novartis Pharmaceuticals

Recruiting

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

Metastatic Uveal Melanoma

United States, Australia, France, Netherlands, Switzerland, Germany, Spain
Ascentage Pharma Group Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Melanoma | P53 Mutation | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Malignant Peripheral Nerve Sheath Tumors | MPNST | Unresectable or Metastatic Melanoma or Advanced Solid Tumors | MDM2 Gene Mutation

United States, Australia
CancerVax Corporation

Unknown

Vaccine Therapy in Treating Patients With Malignant Melanoma

Melanoma (Skin)

United States, Australia
Celgene
ICON Clinical Research

Completed

Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.

Melanoma | Neoplasm Metastasis

Australia, United Kingdom, Ukraine, Germany, Estonia, Latvia, Lithuania, Netherlands, South Africa
Philogen S.p.A.
Eudax S.r.l.

Terminated

Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma

Metastatic Melanoma

Switzerland, Italy, Austria, Germany
Hoffmann-La Roche

Completed

A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma

Malignant Melanoma

United States, Australia
MedtronicNeuro

Completed

Sacral Nerve Stimulation for Anal Incontinence and Bowel Control (MDT-301)

Fecal Incontinence and Constipation

United States, Denmark, Spain, Sweden, Netherlands, Austria, Germany, United Kingdom
Shanghai EpimAb Biotherapeutics Co., Ltd.

Recruiting

A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

Relapsed or Refractory Multiple Myeloma

China, Australia
Peter MacCallum Cancer Centre, Australia

Unknown

Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome

Multiple Myeloma | Myelodysplastic Syndrome | Acute Myeloid Leukaemia

Australia
Merck Sharp & Dohme LLC

Completed

Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)

Melanoma

Australia, South Africa, Spain, Sweden
Melanoma and Skin Cancer Trials Limited
Trans Tasman Radiation Oncology Group

Active, not recruiting

Neurotropic Melanoma of the Head and Neck (RTN2)

Melanoma

United States, Australia, United Kingdom
Monash University
National Health and Medical Research Council, Australia

Recruiting

Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS (SOCRATES)

Melanoma | Atherosclerosis

Australia
Melanoma Institute Australia
Bristol-Myers Squibb; Melanoma and Skin Cancer Trials Limited

Active, not recruiting

Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases (ABC)

Melanoma | Brain Metastases

Australia
Ascendis Pharma Oncology Division A/S

Recruiting

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (IL Believe)

Advanced Solid Tumor | Metastatic Solid Tumor | Platinum-resistant Ovarian Cancer | Locally Advanced Solid Tumor | Post Anti-PD-1 Melanoma | 2L+ Cervical Cancer | Neoadjuvant Melanoma | Neoadjuvant Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Small Cell...

United States, Australia, Korea, Republic of
Plexxikon
Roche Pharma AG

Completed

Safety Study of PLX4032 in Patients With Solid Tumors

Colorectal Carcinoma | Malignant Melanoma

United States, Australia
Melanoma and Skin Cancer Trials Limited
Norfolk and Norwich University Hospitals NHS Foundation Trust; Peter MacCallum...

Active, not recruiting

MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma (MelMarT)

Cutaneous Melanoma by AJCC V7 Stage

United Kingdom, United States, Sweden, Australia, Canada
Actelion

Completed

Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)

Melanoma

Australia
Melanoma and Skin Cancer Trials Limited
Melanoma Institute Australia

Active, not recruiting

Radiotherapy or Imiquimod in Complex Lentigo Maligna (RADICAL)

Lentigo Maligna

Australia, Brazil, New Zealand

Clinical Trials on Facial Melasma in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations